Cellectis (CLLS) Competitors $3.05 +0.20 (+7.02%) Closing price 04:00 PM EasternExtended Trading$2.99 -0.06 (-1.93%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. OPT, ARVN, OLMA, KOD, ATYR, AQST, ESPR, IVA, RAPP, and CYRXShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Opthea (OPT), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Opthea Arvinas Olema Pharmaceuticals Kodiak Sciences aTyr Pharma Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Opthea (NASDAQ:OPT) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation. Does the media prefer OPT or CLLS? In the previous week, Opthea had 1 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Opthea and 2 mentions for Cellectis. Cellectis' average media sentiment score of 1.94 beat Opthea's score of 0.41 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is OPT or CLLS more profitable? Opthea has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. Opthea's return on equity of 0.00% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Cellectis -100.69%-68.05%-21.53% Which has better earnings & valuation, OPT or CLLS? Cellectis has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$30K19,437.00-$162.79MN/AN/ACellectis$49.22M3.44-$36.76M-$0.82-3.72 Which has more risk and volatility, OPT or CLLS? Opthea has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500. Do analysts recommend OPT or CLLS? Opthea presently has a consensus target price of $1.33, indicating a potential downside of 60.90%. Cellectis has a consensus target price of $4.00, indicating a potential upside of 31.15%. Given Cellectis' stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in OPT or CLLS? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 3.2% of Opthea shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCellectis beats Opthea on 9 of the 15 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.41M$3.18B$5.83B$10.07BDividend YieldN/A2.26%5.25%4.53%P/E Ratio-3.727.4956.6922.18Price / Sales3.44453.06536.77117.75Price / CashN/A45.8737.4259.95Price / Book1.299.6011.536.20Net Income-$36.76M-$53.33M$3.29B$270.65M7 Day Performance17.76%0.61%0.44%2.77%1 Month Performance17.31%11.11%10.84%8.83%1 Year Performance37.39%12.61%61.62%27.49% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis2.8803 of 5 stars$3.05+7.0%$4.00+31.1%+26.7%$158.41M$49.22M-3.72290Short Interest ↑High Trading VolumeOPTOpthea0.363 of 5 stars$3.41+7.2%$1.33-60.9%+8.6%$583.10M$30K0.008Upcoming EarningsGap UpHigh Trading VolumeARVNArvinas3.1082 of 5 stars$7.94+1.4%$19.76+148.9%-68.2%$574.86M$263.40M-7.86420Positive NewsOLMAOlema Pharmaceuticals2.4566 of 5 stars$7.58-8.8%$24.00+216.6%-40.4%$570.35MN/A-3.8370Positive NewsKODKodiak Sciences3.6551 of 5 stars$9.79-6.9%$11.75+20.0%+322.7%$555.68MN/A0.0090ATYRaTyr Pharma2.3626 of 5 stars$5.46-2.7%$23.25+325.8%+181.0%$549.71M$230K0.0053AQSTAquestive Therapeutics2.7635 of 5 stars$5.01-7.6%$10.29+105.3%+6.2%$540.50M$57.56M-7.16160News CoverageAnalyst ForecastInsider TradeESPREsperion Therapeutics4.0027 of 5 stars$2.51-6.3%$7.00+178.9%+49.4%$540.35M$332.31M-5.12200Positive NewsIVAInventiva2.9324 of 5 stars$5.37-3.6%$14.83+176.2%+143.6%$532.84M$9.95M0.00100Gap DownRAPPRapport Therapeutics2.4506 of 5 stars$31.47+119.2%$31.00-1.5%+42.6%$524.11MN/A0.00N/ATrending NewsAnalyst ForecastInsider TradeOptions VolumeGap DownHigh Trading VolumeCYRXCryoPort3.9243 of 5 stars$10.04-3.0%$12.00+19.5%+27.9%$518.19M$228.38M7.551,186News CoveragePositive News Related Companies and Tools Related Companies OPT Alternatives ARVN Alternatives OLMA Alternatives KOD Alternatives ATYR Alternatives AQST Alternatives ESPR Alternatives IVA Alternatives RAPP Alternatives CYRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
